Pharmaceutical Congress: Responding to the Guidance

Slides:

Advertisements

Similar presentations

Our role in the U.S. pharmaceutical supply chain:

Advertisements

4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.

NCPIE CMI Initiative. Education Committee Members American Pharmacists Association First DataBank National Assn. of Boards of Pharmacy National Assn.

Grievance Policy - recent changes. Background A new single grievance procedure was agreed in November 05 to address the Dispute Resolution Regulations.

The Importance of Transparency in Regulatory Reform WTO Committee on Technical Barriers to Trade, Workshop on Good Regulatory Practice Panel on Internal.

Continuous Auditing Global Technology Auditing Guide 3 Twelfth Continuous Auditing and Reporting Symposium Rutgers Business School November.

Participant Challenge Pilot Program Participant Stage One Assess, Learn and Develop.

Policies to Prevent Pharmaceutical Waste: Looking at Sample Waste Product Stewardship Institute, Inc. June 4, 2012.

1 IT Security Awareness, Training and Education Trends Dan Costello Policy Analyst OMB.

GENERALLY ACCEPTED AUDITING STANDARDS Profesor Juan M. García Merced.

Clinical Compliance Programs: Investigator Payments, GCPs, and More…. Teri Crouse, J.D. Director of Compliance for Healthcare & Marketing.

Regulatory Requirements & Compliance: Ensuring Effective Outcomes Presented By: John E. Palmer, CPA Managing Director/Principal.

# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.

Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,

Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.

Professionalism and Fitness to Practise processes Results from our medical school survey 1 May 2015 Dr Victoria Gauden Policy Manager GMC.

Internal Audit’s Role in Compliance Laurisa Riggan, CPA, CHE Children’s Mercy Hospitals and Clinics September 26, 2000.

Complaints and Monitoring (s.9 and 10) Malika Ladha PAAB Reviewer.

Pharmacy Administrator: Manager / Adminstrator for Pharmacies Research Leader for: oUoUniversities oHoHealth Insurance oPoPharmaceutical Companies.

Software Project Management

+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.

Current Issues in Pharmaceutical and Medical Device Compliance Management Introductory Comments Pharma, Medical Device & Biotech Colloquium June 6, 2005.

The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.

Pharmaceutical Regulatory and Compliance Congress Special Pre-Conference Workshop: HHS OIG Model Compliance Guidance November 13, 2002.

IDENTIFYING AND RESPONDING TO POTENTIAL VIOLATIONS David Anderson David Anderson Healthcare Compliance Office, Internal Investigator Genentech, Inc. Dan.

Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.

© Hogan & Hartson LLP. All rights reserved. National Pharma Audioconference Bristol-Myers Squibb 2007 Settlement Stephen J. Immelt, Esq. November 26, 2007.

1 Copyright Venable LLP All Rights Reserved. The Future of Pharma Compliance: An Interactive Quiz Janet Rehnquist, Esq. Co-Chair, Health Care Practice,

How to Operationalize the Guidance In A Pharmaceutical Company OIG Guidance Pharma Audioconference Doug Lankler May 21, 2003.

Adult Learners. Self-directed Have personal experience Provide their own motivation Create their own standards.

Audits Allegations Secret Shops Corrective Actions.

Internal Audit ARRA Audit. Background Internal Audit is aware that sometime during 2010 / 2011: – NSF OIG and SAO will conduct audits related to ARRA.

Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.

Enforcement Trends in the Pharmaceutical Industry Lewis Morris Chief Counsel Office of Inspector General, DHHS.

Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,

California Department of Public Health / 1 CALIFORNIA DEPARTMENT OF PUBLIC HEALTH Standards and Guidelines for Healthcare Surge during Emergencies How.

0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.

Greg Levine. January 9, Enforcement Environment  Accelerating progression of off-label promotion cases – Not just “Big Pharma” – No “oncology exception”

1 Building a Compliance Program in a Small Cap Company The Seventh Annual Pharmaceutical Compliance and Best Practices Forum November 9, 2006 Colleen CravenJanice.

Championing the Champions Panelists: John Frahlich: The Ohio Association for College Admission Counseling MorraLee Keller: The Ohio College Access Network.

All Hands Electronic Information Integrity Call White Paper An Introduction to the Current State of EMR – et.al. R. L. Chamberlain, Ph.D.

Setting the Stage: Ten of the Toughest Compliance Questions in Medical and Clinical Affairs International Pharmaceutical Compliance Summit March 30, 2005.

Fraud Enforcement Risks and Compliance Solutions Katie Arnholt Deputy Branch Chief Office of Counsel to the Inspector General.

Kings Specialty Pharmacy Services in Brooklyn

Accountability & Structured Privacy Management

Track 11 Symposium 27 June :30 – 3:00 PM

Quality Metrics for better Quality Compliance

PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.

2016 Improving Data, Improving Outcomes Conference

Monitoring and Tracking in Companies with Small Compliance Departments

Background First ERP written in 1991 Revised in 1998

Update on the OIG’s Investigations Involving Clinical Research

Seven Ways To Protect Your Company

Group Discussion 1: Structure & Organisation of a research society

Risk Management: why and how to protect your health center

UMR account management team

Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.

California’s “Comprehensive Compliance Program” Law

Timothy B. Cleary, Esq. Meredith Manning, Esq.

Compliance at MCHS.

Living With a Corporate Integrity Agreement

Fy18-19 Compliance Plan Review & Board Member Training

C.2.10 Sample Questions.

C.2.8 Sample Questions.

Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.

C.2.8 Sample Questions.

Written complaint about CSP member received by Complaints Co-ordinator

Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.

Presentation transcript:

Pharmaceutical Congress: Responding to the Guidance Spring 2003

OIG Pharma Guidance Panel Members

Implications of the OIG Guidance Key Improvements Biggest Challenges

OIG Pharma Guidance Will it prompt reassessment of written Standards of Conduct?

OIG Pharma Guidance Effects on Compliance Training?

OIG Pharma Guidance Pharmacy Benefit Managers What changes to Companies compliance programs?

OIG Pharma Guidance Drug Samples Changes to the processes relating to the monitoring or tracking of samples?

OIG Pharma Guidance Data Integrity How will compliance programs evolve to address the OIG’s concerns?

OIG Pharma Guidance Role of Compliance Officers Any Changes?

OIG Pharma Guidance Audience Questions?